4.6 Article

Low miR-150-5p and miR-320b Expression Predicts Reduced Survival of COPD Patients

期刊

CELLS
卷 8, 期 10, 页码 -

出版社

MDPI
DOI: 10.3390/cells8101162

关键词

miRNA; COPD; cancer; survival

资金

  1. Deutsche Krebshilfe [111450]
  2. Competence Network Asthma/COPD - German Federal Ministry of Education and Research [FKZ 01GI1001]
  3. AstraZeneca GmbH
  4. Bayer Schering, Pharma AG
  5. Chiesi GmbH
  6. GlaxoSmithKline
  7. Grifols Deutschland GmbH
  8. MSD Sharp Dohme GmbH
  9. Mundipharma GmbH
  10. Novartis Deutschland GmbH
  11. Pfizer Pharma GmbH

向作者/读者索取更多资源

Chronic obstructive pulmonary disease (COPD) is associated with an increased risk of death, reducing life expectancy on average between 5 and 7 years. The survival time after diagnosis, however, varies considerably as a result of the heterogeneity of COPD. Therefore, markers that predict individual survival of COPD patients are of great value. We analyzed baseline molecular profiles and collected 54 months of follow-up data of the cohort study COPD and SYstemic consequences-COmorbidities NETwork (COSYCONET). Genome-wide microRNA signatures from whole blood collected at time of the inclusion in the study were generated for 533 COPD patients including patients that deceased during the 54-month follow-up period (n = 53) and patients that survived this period (n = 480). We identified two blood-born microRNAs (miR-150-5p and miR-320b) that were highly predictive for survival of COPD patients. The expression change was then confirmed by RT-qPCR in 245 individuals. Ninety percent of patients with highest expression of miR-150-5p survived the 54-month period in contrast to only 50% of patients with lowest expression intensity. Moreover, the abundance of the oncogenic miR-150-5p in blood of COPD patients was predictive for the development of cancer. Thus, molecular profiles measured at the time of a COPD diagnosis have a high predictive power for the survival of patients.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据